Regulatory development
On 5 November 2026 the TGA reported label–content discrepancies in tested Synedica peptide products identified while assisting NSW Police. This is a regulatory laboratory safety alert, not a peer-reviewed clinical outcomes study.
TB-500 was not detected in tested BPC 157 & TB 500 10 mg, KLOW 80 mg and BARBIE KLOW 100 mg products. Tested Retatrutide 10 mg products contained less retatrutide than labelled, with significant between-sample variation. Strengths quoted here identify labelled products; they are not measured concentrations or dosing recommendations.
Primary care relevance
The TGA advises cessation of Synedica peptide use, pharmacy disposal, health-professional assessment for concerns after exposure, and adverse-event reporting. A practical editorial implication is to include online or non-prescribed peptide use in a non-judgemental medication history and document the product identity where available. This is not a validated management pathway.
Synedica products have not undergone TGA assessment for quality, safety or efficacy, and their manufacturing location is not approved. The alert highlights serious allergic reactions, including anaphylaxis, but supplies no event rate. Retatrutide remains investigational; the TGA states it is not approved by it or a comparable regulator. The alert supports neither substitution with another unapproved peptide nor dose adjustment to compensate for unreliable labelling.
Evidence limits
The notice provides no sample denominator, assay details, detection limits, exact retatrutide results or linked clinical outcomes. Population prevalence, absolute harm risk and batch-wide generalisability cannot be estimated. Trial funding/conflict appraisal is not applicable to this regulatory notice; it is not evidence of treatment efficacy.
Prepared with AI assistance from the TGA safety advisory. This article summarises the regulator’s findings for primary care.
Primary source
TGA safety alert: testing of Synedica peptide products (5 November 2026). Accessed 8 November 2026 (AEDT).